A Phase 2b Double-Blind, Placebo-Controlled, Adaptive, Dose-Escalation Study to Evaluate the Safety and Efficacy of OnabotulinumtoxinA for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique, in Subjects Undergoing Open Abdominal Ventral Hernia Repair
Latest Information Update: 21 May 2024
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Postoperative pain
- Focus Therapeutic Use
- Sponsors AbbVie
- 13 May 2024 Planned End Date changed from 19 May 2025 to 26 Sep 2025.
- 13 May 2024 Planned initiation date changed from 29 Dec 2023 to 7 May 2024.
- 13 May 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.